» Articles » PMID: 15039299

Quantitative Contribution of CYP2D6 and CYP3A to Oxycodone Metabolism in Human Liver and Intestinal Microsomes

Overview
Specialty Pharmacology
Date 2004 Mar 25
PMID 15039299
Citations 67
Authors
Affiliations
Soon will be listed here.
Abstract

Oxycodone undergoes N-demethylation to noroxycodone and O-demethylation to oxymorphone. The cytochrome P450 (P450) isoforms capable of mediating the oxidation of oxycodone to oxymorphone and noroxycodone were identified using a panel of recombinant human P450s. CYP3A4 and CYP3A5 displayed the highest activity for oxycodone N-demethylation; intrinsic clearance for CYP3A5 was slightly higher than that for CYP3A4. CYP2D6 had the highest activity for O-demethylation. Multienzyme, Michaelis-Menten kinetics were observed for both oxidative reactions in microsomes prepared from five human livers. Inhibition with ketoconazole showed that CYP3A is the high affinity enzyme for oxycodone N-demethylation; ketoconazole inhibited >90% of noroxycodone formation at low substrate concentrations. CYP3A-mediated noroxycodone formation exhibited a mean K(m) of 600 +/- 119 microM and a V(max) that ranged from 716 to 14523 pmol/mg/min. Contribution from the low affinity enzyme(s) did not exceed 8% of total intrinsic clearance for N-demethylation. Quinidine inhibition showed that CYP2D6 is the high affinity enzyme for O-demethylation with a mean K(m) of 130 +/- 33 microM and a V(max) that ranged from 89 to 356 pmol/mg/min. Activity of the low affinity enzyme(s) accounted for 10 to 26% of total intrinsic clearance for O-demethylation. On average, the total intrinsic clearance for noroxycodone formation was 8 times greater than that for oxymorphone formation across the five liver microsomal preparations (10.5 microl/min/mg versus 1.5 microl/min/mg). Experiments with human intestinal mucosal microsomes indicated lower N-demethylation activity (20-50%) compared with liver microsomes and negligible O-demethylation activity, which predict a minimal contribution of intestinal mucosa in the first-pass oxidative metabolism of oxycodone.

Citing Articles

Active CNS delivery of oxycodone in healthy and endotoxemic pigs.

Ballgren F, Bergfast T, Ginosyan A, Mahajan J, Lipcsey M, Hammarlund-Udenaes M Fluids Barriers CNS. 2024; 21(1):86.

PMID: 39443944 PMC: 11515623. DOI: 10.1186/s12987-024-00583-z.


Genetic background and sex influence somatosensory sensitivity and oxycodone analgesia in the Hybrid Rat Diversity Panel.

Duffy E, Ward J, Hale L, Brown K, Kwilasz A, Saba L Genes Brain Behav. 2024; 23(2):e12894.

PMID: 38597363 PMC: 11005106. DOI: 10.1111/gbb.12894.


Importance of cytochrome 3A4 and 2D6-mediated drug-drug interactions in oxycodone consumption among older adults hospitalized for hip fracture: a cross-sectional study.

Decaix T, Gautier S, Royer L, Laprevote O, Tritz T, Siguret V Aging Clin Exp Res. 2023; 35(11):2471-2481.

PMID: 37861957 DOI: 10.1007/s40520-023-02569-7.


Hydrocodone, Oxycodone, and Morphine Metabolism and Drug-Drug Interactions.

Coates S, Lazarus P J Pharmacol Exp Ther. 2023; 387(2):150-169.

PMID: 37679047 PMC: 10586512. DOI: 10.1124/jpet.123.001651.


An Integrative Approach to Elucidate Mechanisms Underlying the Pharmacokinetic Goldenseal-Midazolam Interaction: Application of In Vitro Assays and Physiologically Based Pharmacokinetic Models to Understand Clinical Observations.

Nguyen J, Tian D, Tanna R, Arian C, Calamia J, Rettie A J Pharmacol Exp Ther. 2023; 387(3):252-264.

PMID: 37541764 PMC: 10658920. DOI: 10.1124/jpet.123.001681.